Migraine Drugs Market Research Report - Global Forecast till 2030

Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2030

ID: MRFR/HC/6907-HCR | February 2021 | Region: Global | 100 Pages         

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL MIGRAINE DRUGS MARKET, BY TYPE

6.1. Overview

6.2. Episodic Migraine

6.2.1. Market Estimates & Forecast, by Region, 2020-2027

6.2.2. Market Estimates & Forecast, by Country, 2020-2027

6.3. Chronic Migraine

6.3.1. Market Estimates & Forecast, by Region, 2020-2027

6.3.2. Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Acute

7.2.1. Market Estimates & Forecast, by Region, 2020-2027

7.2.2. Market Estimates & Forecast, by Country, 2020-2027

7.3. Preventive

7.3.1. Market Estimates & Forecast, by Region, 2020-2027

7.3.2. Market Estimates & Forecast, by Country, 2020-2027

7.4. Neuromodulation

7.4.1. Market Estimates & Forecast, by Region, 2020-2027

7.4.2. Market Estimates & Forecast, by Country, 2020-2027

7.5. Others

8. GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS

8.1. Overview

8.2. Beta Blockers

8.2.1. Market Estimates & Forecast, by Region, 2020-2027

8.2.2. Market Estimates & Forecast, by Country, 2020-2027

8.3. Angiotensin Blockers

8.3.1. Market Estimates & Forecast, by Region, 2020-2027

8.3.2. Market Estimates & Forecast, by Country, 2020-2027

8.4. Tricyclics

8.4.1. Market Estimates & Forecast, by Region, 2020-2027

8.4.2. Market Estimates & Forecast, by Country, 2020-2027

8.5. Anticonvulsants

8.5.1. Market Estimates & Forecast, by Region, 2020-2027

8.5.2. Market Estimates & Forecast, by Country, 2020-2027

8.6. Triptans

8.6.1. Market Estimates & Forecast, by Region, 2020-2027

8.6.2. Market Estimates & Forecast, by Country, 2020-2027

8.7. Others

9. GLOBAL MIGRAINE DRUGS MARKET, BY END USER

9.1. Overview

9.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Retail Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Online Pharmacy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL MIGRAINE DRUGS MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. UK

10.3.1.4. Italy

10.3.1.5. Spain

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. China

10.4.2. India

10.4.3. Japan

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPETITIVE LANDSCAPE

11.1. Introduction

11.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Allergan Plc

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Product Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Alder Biopharmaceuticals, Inc.

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Product Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. Pfizer Inc

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Product Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. GlaxoSmithKline Plc

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Product Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Merck & Co., Inc.

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Product Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Teva Pharmaceutical Industries Ltd

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Product Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. AstraZeneca Plc

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Product Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Johnson & Johnson Services, Inc.

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Product Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. Amgen Inc

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Product Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Eli Lilly and Company

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Product Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. eNeura Inc.

12.11.1. Company Overview

12.11.2. Financial Overview

12.11.3. Product Offered

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Others

13. APPENDIX

13.1.1. Discussion Blueprint

13.1.2. Related Reports

NOTE:

This table of content is tentative and subject to change as the research progresses.

 In section 10, only the top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.

 Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.


LIST OF TABLES

TABLE 1 GLOBAL MIGRAINE DRUGS MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL MIGRAINE DRUGS MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL MIGRAINE DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL MIGRAINE DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 10 US: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 12 US: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 13 CANADA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 15 CANADA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 16 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 19 EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 22 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 25 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 28 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY END USER, 2020-2027(USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MIGRAINE DRUGS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MIGRAINE DRUGS MARKET

FIGURE 4 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 5 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY DRUG CLASS, 2020 (%)

FIGURE 6 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY END USER, 2020(%)

FIGURE 7 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: MIGRAINE DRUGS MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL MIGRAINE DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ALLERGAN PLC.: KEY FINANCIALS

FIGURE 16 ALLERGAN PLC: SEGMENTAL REVENUE

FIGURE 17 ALLERGAN PLC: REGIONAL REVENUE

FIGURE 18 PFIZER INC.: KEY FINANCIALS

FIGURE 19 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 20 PFIZER INC.: REGIONAL REVENUE

FIGURE 21 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 22 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 23 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 24 MERCK & CO., INC. KEY FINANCIALS

FIGURE 25 MERCK & CO., INC.: SEGMENTAL REVENUE

FIGURE 26 MERCK & CO., INC.: REGIONAL REVENUE

FIGURE 27 TEVA PHARMACEUTICALS INDUSTRIES LTD: KEY FINANCIALS

FIGURE 28 TEVA PHARMACEUTICALS INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 29 TEVA PHARMACEUTICALS INDUSTRIES LTD: REGIONAL REVENUE

FIGURE 30 ASTRAZENECA PLC: KEY FINANCIALS

FIGURE 31 ASTRAZENECA PLC: SEGMENTAL REVENUE

FIGURE 32 ASTRAZENECA PLC: REGIONAL REVENUE

FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS

FIGURE 34 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 35 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE

FIGURE 36 AMGEN INC: KEY FINANCIALS

FIGURE 37 AMGEN INC: SEGMENTAL REVENUE

FIGURE 38 AMGEN INC: REGIONAL REVENUE

FIGURE 39 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 40 ELI LILLY AND COMPANYSEGMENTAL REVENUE

FIGURE 41 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 42 ENERA INC: KEY FINANCIALS

FIGURE 43 ENERA INC: SEGMENTAL REVENUE

FIGURE 44 ENERA INC: REGIONAL REVENUE

Migraine Drugs Market

Migraine Drugs Market is projected to reach USD 6986.02 million at a CAGR of 3.65% by 2030

Segmentation

By Type Episodic Migraine Chronic Migraine
By Treatment Type Acute Preventive Neuromodulation Devices
By Drug Class Triptans Betablockers Angiotensin Blockers Tricyclics Anticonvulsants
By End-User Hospitals And Clinics Retail Pharmacy Online Pharmacy Others

Key Players

  • Allergan Plc (Ireland)
  • Alder Biopharmaceuticals Inc. (US)
  • Pfizer Inc. (US)
  • GlaxoSmithKline Plc (UK)
  • Merck & Co. Inc. (US)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • AstraZeneca PLC (UK)
  • Johnson & Johnson Services Inc. (US)
  • Amgen Inc. (US)
  • Eli Lilly and Company

Drivers

  • Increasing prevalence of migraine worldwide
  • Rapidly changing lifestyle
  • Increased uptake of novel drug classes
Speak to Analyst Request a Free Sample

Migraine Drugs Market Overview


Migraine Drugs Market is projected to reach USD 6986.02 million at a CAGR of 3.65% by 2030, says Market Research Future (MRFR) . Migraine is a medical ailment that is characterized by severe headaches and other symptoms such as nausea and hypersensitivity to smell. These headaches often affect only one side of the head, and each migraine episode is unique in terms of duration and intensity. Migraine medications are used to treat headaches linked with migraine.


For many years, the market for prescription acute and preventive migraine therapies has been stable — and primarily generic — but is now ready for change. The increasing prevalence of migraine fuels the demand for migraine medications. Seven or more of these high-cost, creative new medications target calcitonin gene-related peptide (CGRP), a critical pathogenic component in migraine and a long-desired, but previously elusive, therapeutic target. These are the first new migraine-specific medication classes to be introduced in almost two decades. Additionally, the growing female population and increased awareness among patients regarding migraine prevention and treatment are major drivers driving the market's growth.


However, the adverse effects associated with migraine medications act as a restraint on the market's expansion. On the contrary, the emergence of growth potential in emerging economies is projected to open up new avenues for significant participants. Additionally, hormonal drugs such as oral contraceptives and hormone replacement therapy may exacerbate migraine symptoms in females. As a result, the growing worldwide female population is expected to fuel the expansion of the migraine medications market.


Migraine Drugs Market Influencer


The increasing prevalence of migraine is expected to contribute to the growth of the migraine drugs market during the forecast period.


Market Drivers



  • Increasing prevalence of migraine worldwide. As of January 2019, 2.9% of the deaths occurred due to migraine worldwide.

  • Rapidly changing lifestyle

  • Growing awareness programs regarding the prevention and treatment of migraine

  • Rising R&D investment for the development of innovative drugs for the treatment of migraine

  • Increased uptake of novel drug classes and the introduction of peptide-based therapies for the treatment of migraine


Market Restraints



  • Stringent government regulations

  • High investment required for drug research and development

  • Side-effects of medications prescribed for migraine


Migraine Drugs Market Segmentation


By Type



  • Episodic Migraine: It is characterized by patients with migraine who have 0 to 14 headache days per month. This segment holds the highest share in the migraine drugs market.

  • Chronic Migraine: It is characterized by patients with migraine who have 15 or more headache days per month. This segment is expected to grow faster during the forecast period. Chronic migraine affected approximately 2% of the global population.


By Treatment type



  • Acute: It is the largest segment. It represents approximately 90% of the share in the Migraine Drugs Market. This segment is expected to register a CAGR of 6.1% during the forecast period. All the patients suffering from migraine require acute therapy, regardless of whether they are also treated with preventative therapy. In addition to this, acute treatments are also used in combination with preventive treatments. Major companies in the migraine drugs market are conducting R&D of novel acute therapeutics, and it is expected that 5 to 8 major drugs will be launched that will boost the market during the forecast period.

  • Preventive: It is the second-largest segment in the market. It holds 8% share in the migraine drugs market. Preventative treatments reduce frequency and disability of migraine. The major drugs classes included in preventive treatments are beta-blockers, botulin toxins, and topiramate.

  • Neuromodulation Devices: It is the fastest segment in the market. It holds approximately 2% share in the market. There are three major FDA approved neuromodulation devices for the treatment of migraine in the US migraine drugs market.  


By Drug Class



  • Triptans: It holds the highest share in the migraine drugs market. It is used in the acute treatment of migraine.

  • Betablockers: These are majorly used in the preventive migraine therapeutics.

  • Angiotensin Blockers: These are used as preventive headache treatments for chronic migraine.

  • Tricyclics: These are used as preventive headache treatments for chronic migraine. Tricyclic antidepressants (TCAs) are the first agents shown to be effective in the prophylaxis of migraine.

  • Anticonvulsants: These drugs prevent seizures, headaches, and acute migraines. Topiramate (Qudexy XR, Topamax) and valproic acid (Depakene, Depakote) anticonvulsants are used for the treatment of acute migraine


By End-User



  • Hospitals and Clinics: The largest segment. Hospitals and clinics are the primary points of care for the treatment of migraine. Rising prevalence of migraine is expected to drive the market growth.

  • Retail Pharmacy: It is the second largest segment and provides prescribed migraine drugs for chronic migraine conditions and over the counter migraine drugs for acute migraine conditions.

  • Online Pharmacy: It is the fastest-growing segment which provides migraine drugs through e-commerce platforms. The drug class majorly offered by online pharmacy chains are for acute migraine treatment

  • Others: This segment includes centers for home care and elderly population.


By Region



  • Americas: The largest regional migraine drugs market. The prevalence of migraine is high in the Americas. Approximately, 12% of the US population including 18% of women, 6% of men, and 10% of the children were suffering from different types of migraines in the US as of December 2018. Moreover, the healthcare infrastructure in the Americas is also developed, which contributes to market growth. Furthermore, major pharmaceutical companies such as Pfizer Inc. and Alder Biopharmaceuticals, Inc. are headquartered in the US, which positively contributes to the growth of the migraine drugs market in the Americas.



  • Europe: An increasing prevalence of neurological diseases including migraine in major countries such as the UK, Germany, France, Italy, Spain, and Russia, increasing healthcare expenditure, availability of funds for research, and rising R&D investment for the development of innovative drugs for migraine are anticipated to drive the market growth in Europe. Approximately 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK as of December 2018.



  • Asia-Pacific: The fastest-growing regional migraine drugs market. Asia-Pacific is seeing a surge in the number of people suffering from migraine. Moreover, government and non-government organizations are conducting awareness programs for migraine, which is expected to drive the market growth.



  • Middle East & Africa: The market is expected to show significant growth due to the rising patient population suffering from migraine. The market in the Middle East is expected to show more growth as compared to the African market owing to fast-developing healthcare facilities in the Middle Eastern countries such as Saudi Arabia, Qatar, and Oman.


Migraine Drugs Market Key Players



  • Allergan Plc (Ireland)

  • Alder Biopharmaceuticals, Inc. (US)

  • Pfizer Inc. (US)

  • GlaxoSmithKline Plc (UK)

  • Merck & Co., Inc. (US)

  • Teva Pharmaceutical Industries Ltd (Israel)

  • AstraZeneca PLC (UK)

  • Johnson & Johnson Services, Inc. (US)

  • Amgen Inc. (US)

  • Eli Lilly and Company

  • eNeura Inc.


Industry Updates


February 2022: Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. published good top-line results from a Phase 3 clinical trial in 1,431 adults in Asia-Pacific evaluating rimegepant for the immediate treatment of migraine. The randomized, regional, multi-center research, led by BioShin Limited, a subsidiary of Biohaven in China and South Korea, fulfilled the co-primary endpoints evaluating the efficacy and safety of rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist.



Report Scope:
Report Attribute/Metric Details
  Market Size   2030 : USD 6986.02 Billion
  CAGR   3.65%. (2020 -2030)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Treatment, Drug Class, End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca PLC (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc. (US), Eli Lilly and Company, eNeura Inc.
  Key Market Opportunities   Rising R&D investments for the innovative drug discoveries for the treatment of the condition.
  Key Market Drivers

  • Increasing prevalence of migraine worldwide
  • Rapidly changing lifestyle
  • Increased uptake of novel drug classes


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The global migraine drugs market is projected to reach a valuation of USD 6986.02 mN by 2030.

    The global migraine drugs market is projected to grow at approximately 3.65% CAGR during forecast period (2020-2030).

    Rising R&D investments for the innovative drug discoveries for the treatment of the condition.

    North America holds the largest share in the global migraine drugs market, followed by Europe and the Asia Pacific, respectively.

    Alder Biopharmaceuticals, Inc. (US), Allergan Plc (Ireland), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline Plc (UK), Teva Pharmaceutical Industries Ltd (Israel), Johnson & Johnson Services, Inc. (US), AstraZeneca PLC (UK), Amgen Inc. (US), and Eli Lilly and Company eNeura Inc., are some of the major players operating in the migraine drugs market.